Asthma drugs and the risk of congenital anomalies.
To estimate the prevalence of congenital anomalies between the offspring of women exposed and unexposed to asthma drugs during early pregnancy. Matched cohort study. The United Kingdom's General Practice Research Database. Women exposed to asthma drugs during early pregnancy and a sample of matched unexposed pregnant women. The prevalence of any anomaly among unexposed and exposed women was 27.8 (95% confidence interval [CI] 25.4-30.6)/1000 pregnancies and 31.3 (95% CI 27.7-35.5)/1000 pregnancies, respectively (relative risk [RR] 1.1 95% CI 1.0-1.3). Our findings suggest that asthma drugs, overall, do not increase the risk of congenital anomalies in the offspring when taken during the first trimester of pregnancy.